Autoimmune Diseases

Safety of COVID-19 Vaccination in Those with MS, NMOSD, and MOGAD

A recent paper outlined the findings of a new study on the safety and efficacy of COVID-19 vaccines in patients with Multiple Sclerosis (MS), Neuromyelitis Optica spectrum disorder (NMOSD), and Myelin Oligodendrocyte Glycoprotein antibody disease (MOGAD). Researchers in South Korea examined the medical records of 56 patients (19 with MS, 22 with NMOSD, and 15 with MOGAD) to determine the effects of vaccination on this population. 

Read More »

COVID-19 Vaccination in Adults with Inflammatory Bowel Disease

A recent review article covers current knowledge about COVID-19 vaccination in those with inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis. The authors concluded that IBD patients are not at increased risk of infection or serious illness from Covid-19. With the exception of patients taking corticosteroids, most IBD therapies have been shown not to increase the risk of covid-19.

Read More »

Molnupiravir & Nirmatrelvir/Ritonavir in the Treatment of Systemic Autoimmune Rheumatic Diseases

Molnupiravir (MP) and Nirmatrelvir/ritonavir (NM/R) were the first two orally administered antiviral drugs authorized to treat COVID-19. However, the last two phases of clinical trials testing MP and NM/R in COVID-19 were conducted in unvaccinated individuals and before the emergence of the Omicron variant. Additionally, clinical trials didn’t include people suffering from systemic autoimmune rheumatic diseases (SARDs).

Read More »